Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS101 vs Dupixent in moderate-to-severe atopic dermatitis
CTR20260166Phase 3Active
- Sponsor
- Jingxing Pharma
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of GS101 in atopic dermatitis (AD), sponsored by Jingxing Pharma. Started Jan 2026; status: active.
02
Drugs
GS101
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20260166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260166.